Table 1.
Summary of Included Studies
| Study ID | No. Patients (No. Tumors) | Median Age | Tumor size (cc) Median (Range) |
Tumor Grade | Treatment Platform | Dose and Fractionation (Gy/fractions) |
Median Dose (Gy) | IDL Prescribed To | Crude Local Control (%) | Late Toxicity (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Marchetti 201614 |
143 (143) | 52 | 8 (0.1-126) |
50% Grade I 50% presumed Grade I |
CK | 14-25/3-5 | 25 | 65%-86% | 95 | 4.9 |
| Demiral 201615 |
19 (19) | 40 | 26 (4-103) |
100% Grade I | LINAC | 25/5 | 25 | 85%-95% | N/R | 21.1 |
| Conti 201512 |
25 (25) | N/R | 5 (0.3-19) |
N/R | CK | 18/2 18-21/3 20-22/4 23-25/5 |
N/R | 63%-80% | 100 | 8 |
| Haghighi 201511 |
57 (57) | N/R | 7 (N/R) |
38% Grade I 4% Grade II 58% presumed Grade I |
LINAC | 37.5-40/15 | N/R | 75%-100% | 93 | 14 |
| Maranzano 201520 |
77 (80) | 65 | 23 (1-110) |
46% Grade I 15% Grade II 39% presumed Grade I |
LINAC | 45/15 42/14 |
43.5 | 90% (median) |
N/R | 0 |
| Navarria 20159 | 26 (27) | 67 | 13 (2-93) |
N/R | LINAC | 30/5 | N/R | N/R | 100 | N/R |
| Han 201419 |
22 (22) | 62 | N/R | N/R | LINAC | 25/5 | N/R | 90% (median) | 100 | 0 |
| Kaul 201410 |
92 (92) | N/R | N/R | 89% Grade I or presumed Grade I 11% Grade II or III |
LINAC | 37.6 ± 4.4 Gy total dose; 2.2-5 Gy/fraction | N/R | 80% (median) |
N/R | N/R |
| Smith 2014 (abstract)18 |
24 (26) | 60 (mean) |
N/R | N/R | CK | 22.5-30/5 | N/R | N/R | 100 | 8.3 |
| Marchetti 201113 |
21 (21) | 58 | 3 (0.3-23) |
N/R | CK | 25/5 | 25 | 75%-85% | 100 | 9.5 |
| Morimoto 201117 |
31 (32) | 68 | N/R | 100% Grade I or presumed Grade I | CK | 21-36/3-5 | 28 | 90%-100% | 91 | 9.7 |
| Trippa 200916 |
35 (35) | 59 | 23 (4-58) |
94% Grade I or presumed Grade I 6% Grade II |
LINAC | 45/15 42/14 |
N/R | N/R | N/R | 0 |
| Gorman 20087 |
38 (39) | 56 | N/R | 96% Grade I or presumed Grade I 4% Grade II |
LINAC | 35-45/15 | 37.5 | 75%-90% 80% (median) |
100 | 15.8 |
| Pham 20048 |
20 (20) | 53 | 6 (2-19) |
N/R | CK | 15-30/2-5 | 20 | 67%-95% | 90 | 0 |
Abbreviations: CK, CyberKnife; IDL, isodose level; LINAC, linear accelerator; N/R, not reported.